Sackler Family Empire Poised To Win Immunity From Opioid Lawsuits

Jun 2, 2021
Originally published on June 3, 2021 4:41 pm

After more than a year of high-stakes negotiations with billions of dollars on the line, a bankruptcy plan for Purdue Pharma, the maker of OxyContin, cleared a major hurdle late Wednesday.

Federal Judge Robert Drain in White Plains, N.Y., moved the controversial deal forward despite objections from dozens of state attorneys general, setting the stage for a final vote by the company's creditors expected this summer.

The drugmaker filed for Chapter 11 protection in 2019 facing an avalanche of lawsuits tied to its aggressive opioid sales practices.

Public health experts and many government officials say the introduction of OxyContin fueled the nation's deadly opioid epidemic.

This development brings members of the Sackler family, some of whom own Purdue Pharma and served on the company's board of directors, a step closer to winning immunity from future opioid lawsuits.

According to legal documents filed as part of the case, that immunity would extend to dozens of family members, more than 160 financial trusts, and at least 170 companies, consultants and other entities associated with the Sacklers.

"The Sacklers are paying $4.275 billion, and they very much plan and expect to be done with this chapter," said Marshall Huebner, an attorney representing Purdue Pharma, during a hearing last week.

One of the firms that would secure protection from future opioid lawsuits under the deal is Luther Strange & Associates, founded by former U.S. Sen. Luther Strange (R-Ala.), who helped Purdue Pharma pitch the bankruptcy plan to Republican state attorneys general.

While Purdue Pharma has twice pleaded guilty to federal crimes relating to its opioid marketing schemes, no member of the Sackler family has faced criminal charges.

Appearing before a congressional panel last December, members of the Sackler family said they had done nothing wrong. "The family and the board acted legally and ethically," testified David Sackler, who served on Purdue Pharma's board for six years.

In addition to contributing money from their personal fortunes, the Sacklers have agreed to give up control of Purdue Pharma. They will, however, retain ownership of other companies, admit no wrongdoing and will remain one of the wealthiest families in America.

Two dozen states still oppose the bankruptcy deal that has been negotiated largely behind closed doors. They argue it would improperly strip them of authority to sue members of the family for alleged wrongdoing.

"I don't believe ... at this point the plan is confirmable," said Andrew Troop, an attorney representing a coalition of "nonconsenting" states, during a hearing last week.

But Drain said this stage of the bankruptcy process wasn't focused on final approval of the plan.

Instead, the court evaluated whether Purdue Pharma and the Sacklers had provided enough information and transparency to allow creditors to make an informed decision on the deal's financial merits.

Despite a significant veil of secrecy surrounding the proceedings — which included an expansive investigation of the Sacklers that will likely never be made public — Drain signaled the so-called "disclosure statement" was adequate.

Attorneys representing Purdue Pharma and other parties in the bankruptcy process said negotiations continue.

"We are mediating as we speak with the nonconsenting states," Huebner said on Wednesday. "We continue to be open and listen as hard as we can to all other remaining objectors between now and confirmation."

A vote and final approval expected by August

In the coming weeks, more than 600,000 individuals, companies and governments with claims against Purdue Pharma will vote on the package, described by attorneys involved in the process as one of the most complicated and controversial bankruptcies ever.

A final confirmation hearing is scheduled for Aug. 9. Drain has indicated he believes this plan offers the best chance at financial relief for those harmed by Purdue Pharma's OxyContin business.

Supporters of the bankruptcy deal say the alternative would be a chaotic scrum of risky and expensive litigation. "Billions would be spent on legal fees," Huebner said last week. "It would be years until claimants might get a recovery."

The reorganization plan also includes a detailed formula that would be used to distribute hundreds of millions of dollars each year in aid to communities and individuals harmed by opioids.

A growing number of government officials have signaled they expect to vote in favor of the deal.

But critics, including more than 20 mostly Democratic state attorneys general, say the Sacklers are improperly piggybacking on their company's bankruptcy without actually filing for bankruptcy themselves.

"The bankruptcy system should not be allowed to shield non-bankrupt billionaires," said Massachusetts Attorney General Maura Healey in an interview with NPR last month.

Some legal scholars have also questioned whether bankruptcy court is the proper venue for a case that involves an addiction crisis that has killed hundreds of thousands of Americans.

"[T]he most socially important chapter 11 case in history will be determined through a process that does not comport with basic notions of due process," wrote Adam Levitin, who teaches law at Georgetown University, in an article published last month in the Texas Law Review.

In a legal brief filed with the bankruptcy court on Tuesday, Jonathan Lipson, a legal scholar at Temple University who also represents a client with a claim against Purdue Pharma, noted this case is complicated by allegations leveled against the Sacklers by the Justice Department last October. He argues those allegations raise the question of whether some Sacklers could be held responsible for crimes Purdue admitted to.

"These cases have been overshadowed by a single, critical question: who is responsible for [Purdue Pharma's] confessed crimes and the harm they caused?" Lipson wrote in his motion.

Lipson requested an independent examiner be appointed to review whether the Chapter 11 process has been handled appropriately.

Again, the Sacklers have denied any wrongdoing and have never been charged with crimes. As part of their settlement with the DOJ, members of the Sackler family paid $225 million while denying the allegations.

Sackler family pushes back against "false allegations"

During last week's hearing an attorney representing members of the Raymond Sackler branch of the family said they have created a website designed to offer a rebuttal to critics of the Sacklers.

"Raymond Sackler family members have consistently expressed their regret that OxyContin, which continues to help patients suffering from chronic pain, unexpectedly became part of the opioid crisis," the family said in a statement.

In civil lawsuits already filed against the Sacklers, government officials allege some family members had direct knowledge of the highly addictive nature of OxyContin but continued to push Purdue Pharma's sales team to maximize profits.

The DOJ settlement with the Sacklers also included the allegation some family members engaged in "fraudulent" transfers of wealth and approved a marketing plan that focused on pushing OxyContin sales to "extreme, high-volume prescribers."

According to the Justice Department statement, that program led "health care providers to prescribe opioids for uses that were unsafe, ineffective, and medically unnecessary, and that often led to abuse and diversion."

The Sacklers maintain they did nothing wrong and acted ethically. If this bankruptcy plan is approved and upheld on appeal, it's unlikely the allegations will ever be tested in court.

More than 400 civil cases already filed against members of the Sackler family claiming alleged wrongdoing would be halted.

Clarification: 6/02/21

An earlier version of this story was unclear about allegations against members of the Sackler family. The story has been clarified to state that a brief filed in the bankruptcy case argues that allegations leveled by the Justice Department last October could raise the question of whether some members of the Sackler family could be held responsible for crimes Purdue admitted to.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

To other news - the bankruptcy plan for the maker of OxyContin. Purdue Pharma cleared a major hurdle today. If it wins final approval from the company's creditors, the settlement could mean billions of dollars in aid for communities devastated by the opioid crisis. It also would bring members of the Sackler family a big step closer to their goal of winning immunity from future opioid lawsuits for themselves and their financial empire. NPR addiction correspondent Brian Mann is here.

Hey, Brian.

BRIAN MANN, BYLINE: Hey, Mary Louise.

KELLY: All right, so what are the contours of this? What exactly happened this afternoon?

MANN: Yeah, so there have been these incredibly high-stakes negotiations. And as you mentioned, there are billions of dollars at stake. So late today, federal bankruptcy judge Robert Drain here in New York approved the deal's broad terms, allowing it to move forward - a big milestone. Under this plan, the Sacklers will give up control of Purdue Pharma. Though members of the family maintain they did nothing wrong, they have agreed to pay more than $4 billion from their private fortunes. Now, this isn't the final finish line, but it's very close. And now it will go to a vote by hundreds of thousands of creditors who say they were harmed by OxyContin. We really could see a final resolution of this landmark case by this summer.

KELLY: Now, what does this mean for the hundreds of civil lawsuits that some members of the family have faced, alleging they played a personal role in the crisis? I will note the Sacklers deny those allegations, but what happens? If this deal is finalized, what happens to those cases?

MANN: Yeah, this is controversial. Those lawsuits would be stopped dead in their tracks. Under the deal, the Sacklers would walk away from the opioid crisis with a clean slate legally. And we've also learned from these court documents that this immunity would extend to literally hundreds of other companies, trusts and consultants. None of those entities have declared bankruptcy. But using a rare and, again, controversial provision of bankruptcy law, this deal would allow all of those folks to gain protections from lawsuits without actually filing for bankruptcy.

KELLY: Well, let's look at this from a couple of angles. First, the arguments in favor of this deal - why do supporters support it?

MANN: Yeah. Purdue Pharma's legal team made a simple argument that this deal would prevent a firestorm - a chaos of litigation - preventing hundreds of thousands of individual lawsuits. And instead, they say financial help will now go to communities and people harmed by opioids relatively quickly, possibly as soon as next year. A lot of states, as well as local governments, have signaled they will vote for this. You know, with more than 90,000 drug overdose deaths again last year, officials say they need financial help desperately right now.

KELLY: But a couple of dozen state attorneys general opposed this plan. How come?

MANN: Yeah, this is interesting. This deal would force them, they say, to give up their authority to sue members of the Sackler family, even though the Sacklers, again, have not filed for bankruptcy. And these states argue that allows the Sacklers to avoid accountability. They will remain one of the wealthiest families in the country - admit no wrongdoing. And that makes a lot of people angry. A lot of these attorneys general also say it would set a dangerous precedent, allowing other wealthy people to use bankruptcy court like this - protecting themselves from liability, again, without actually ever filing for bankruptcy.

KELLY: And to weave in a little bit of context, we've been talking Purdue Pharma, but there is a big legal reckoning ahead for a lot of companies involved in the opioid business.

MANN: Yeah, this is a fascinating moment. Purdue Pharma and the Sacklers get talked about a lot in this drug epidemic, but there are much bigger corporations that got into the opioid trade - AmerisourceBergen, Johnson & Johnson and Walmart. There are other lawsuits underway all over the country. Tens of billions of dollars are at stake if they're found liable, so this is a big moment for a reckoning, as you say, with the opioid crisis.

KELLY: That is Brian Mann, NPR's addiction correspondent, talking about the bankruptcy deal and its prospects for Purdue Pharma.

Thank you, Brian.

MANN: Thank you so much.

(SOUNDBITE MUSIC) Transcript provided by NPR, Copyright NPR.